Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system that represents the most common non-traumatic cause of neurological disability in young adults worldwide, affecting an estimated two point eight million people globally with a significant predominance in women over men of approximately two to three fold. The disease is characterized by the immune-mediated destruction of myelin, the lipid-rich insulating sheath that surrounds axons and is critical for the rapid and efficient saltatory conduction of electrical impulses along nerve fibers, in conjunction with axonal injury that occurs alongside demyelination and that is increasingly recognized as the primary driver of permanent neurological disability in the condition. The clinical consequences of this widespread central nervous system injury are extraordinarily diverse, reflecting the varied locations of demyelinating lesions across the brain, spinal cord, and optic nerves and producing a clinical picture unique to each affected individual that can encompass virtually any neurological symptom or sign.
The past three decades have witnessed a revolution in the understanding and treatment of multiple sclerosis that has fundamentally transformed the clinical landscape of the disease. The development of magnetic resonance imaging as a sensitive and specific tool for detecting demyelinating lesions in the central nervous system both enabled the early diagnosis of multiple sclerosis before significant disability had accumulated and provided an objective surrogate outcome measure for clinical trials, accelerating the development of disease-modifying therapies. The approval of interferon beta-1b in 1993 inaugurated the modern treatment era, and the subsequent development of more than twenty disease-modifying therapies targeting diverse immunological mechanisms has transformed relapsing multiple sclerosis from a condition managed primarily through symptomatic treatment into one where aggressive early intervention with highly effective therapies can dramatically alter the natural history of the disease and prevent or substantially delay the accumulation of irreversible disability.
Despite these therapeutic advances, multiple sclerosis remains a condition of significant unmet need. Progressive forms of multiple sclerosis, in which disability accumulates independently of acute inflammatory attacks, are substantially less responsive to available immunomodulatory therapies than the relapsing form. Effective remyelination-promoting therapies capable of restoring conduction in demyelinated axons and reversing established disability remain elusive despite active research. The incomplete understanding of why some patients develop severe disability rapidly while others maintain normal function for decades despite a similar number of magnetic resonance imaging lesions reflects the incomplete characterization of the factors governing neurodegeneration in multiple sclerosis.
Immunological Pathogenesis of Multiple Sclerosis
The immunological processes underlying multiple sclerosis involve a complex interplay of adaptive and innate immune cells, inflammatory mediators, and neural tissue responses that collectively produce the demyelinating lesions characterizing the condition. The prevailing understanding positions multiple sclerosis as primarily a T lymphocyte-mediated autoimmune disease in which CD4-positive T lymphocytes reactive against myelin antigens enter the central nervous system, where they reactivate upon encountering their cognate antigen presented by local antigen-presenting cells, and drive an inflammatory cascade that damages myelin and the oligodendrocytes responsible for producing and maintaining it.
The peripheral activation of myelin-reactive T lymphocytes, which must occur before they can enter the central nervous system to initiate lesion formation, reflects a breakdown of the immune tolerance mechanisms that normally prevent autoreactive T lymphocytes from becoming effector cells. The factors triggering this breakdown are incompletely understood but likely involve molecular mimicry, in which immune responses generated against microbial antigens during infections cross-react with structurally similar myelin peptides, and bystander activation, in which the inflammatory environment generated during infection non-specifically lowers the activation threshold of autoreactive T lymphocytes to levels at which they can become activated by self-antigen presentation.
Once activated in the periphery, myelin-reactive CD4-positive T lymphocytes differentiate into Th1 and Th17 effector cells under the influence of interleukin-12 and interleukin-23 respectively. These effector cells upregulate adhesion molecules and chemokine receptors that enable their attachment to the luminal surface of cerebral blood vessels and their migration across the blood-brain barrier into the central nervous system parenchyma. Within the central nervous system, they are reactivated by myelin antigen presentation and release interferon gamma, interleukin-17, and tumor necrosis factor, cytokines that activate resident microglia, recruit additional peripheral immune cells including CD8-positive cytotoxic T lymphocytes and B lymphocytes, and directly damage oligodendrocytes and myelin through cytokine-mediated and contact-dependent cytotoxic mechanisms.
The role of B lymphocytes in multiple sclerosis pathogenesis has received increasing recognition in recent years, supported by the remarkable clinical efficacy of B lymphocyte-depleting therapies with ocrelizumab and ofatumumab that substantially reduce both relapse rates and magnetic resonance imaging lesion activity in relapsing multiple sclerosis. B lymphocytes contribute to multiple sclerosis through multiple mechanisms beyond their capacity to produce antibodies against myelin antigens: they serve as efficient antigen-presenting cells that stimulate myelin-reactive T lymphocytes, produce pro-inflammatory cytokines including lymphotoxin and interleukin-6 that amplify the neuroinflammatory environment, and within the central nervous system form organized lymphoid aggregates in the meninges that are associated with more aggressive cortical pathology and faster disability accumulation in progressive multiple sclerosis.
Innate immune cells, particularly microglia and macrophages, play critical roles in both the effector phase of acute demyelinating lesion formation and in the chronic smoldering neuroinflammation that drives progressive multiple sclerosis. Activated microglia and macrophages are the dominant cellular components of chronic active lesions, the pathological lesion type most strongly associated with disability progression in both relapsing and progressive multiple sclerosis. In chronic active lesions, a slowly expanding rim of activated microglia and macrophages at the lesion edge continues to generate oxidative stress and cytokine-mediated damage to axons and oligodendrocytes for years after the initial acute inflammatory event, contributing to the insidious, gradual disability accumulation of progressive multiple sclerosis through mechanisms largely inaccessible to current peripherally-acting immunomodulatory therapies.
Clinical Phenotypes and Disease Course
Multiple sclerosis presents in several distinct clinical phenotypes that reflect different patterns of inflammatory disease activity and neurodegeneration. Relapsing-remitting multiple sclerosis is the most common initial phenotype, affecting approximately eighty-five percent of newly diagnosed patients and characterized by discrete episodes of new or worsening neurological symptoms, termed relapses or exacerbations, that develop over hours to days, reach their nadir over one to three weeks, and then partially or completely resolve over subsequent weeks to months as remyelination and resolution of inflammation restore conduction in affected pathways. Between relapses, patients in the relapsing-remitting phase experience no objective clinical worsening by definition, though subclinical disease activity detectable on magnetic resonance imaging continues during apparent clinical stability.
The clinical manifestations of multiple sclerosis relapses reflect the anatomical location of the new or enlarging demyelinating lesion responsible for the clinical event. Optic neuritis, presenting as subacute unilateral visual loss with pain on eye movement, is the presenting manifestation in approximately twenty-five percent of multiple sclerosis patients and reflects demyelination of the optic nerve. Brainstem and cerebellar syndromes produce diplopia, vertigo, ataxia, dysarthria, and dysphagia through demyelination of the relevant brainstem tracts and cerebellar connections. Spinal cord lesions produce sensory disturbances including the Lhermitte sign, a tingling electrical sensation radiating down the spine on neck flexion, as well as limb weakness, spasticity, and bladder dysfunction that are among the most functionally disabling manifestations of multiple sclerosis. Fatigue, the symptom reported as most disabling by the greatest proportion of multiple sclerosis patients, is present across all disease phenotypes and does not necessarily correlate with lesion burden or disability level, reflecting its complex pathophysiology involving both direct central nervous system mechanisms and secondary contributors including depression, sleep disturbance, and deconditioning.
Secondary progressive multiple sclerosis develops in a proportion of patients with relapsing-remitting multiple sclerosis after a variable period of relapsing disease, characterized by the onset of steady, gradual disability accumulation that progresses independently of acute inflammatory attacks. The transition to secondary progressive multiple sclerosis reflects the accumulation of sufficient axonal damage and loss that the neurological reserve available to compensate for the ongoing injury is exhausted, and further neurodegeneration produces clinically manifest disability even in the absence of new inflammatory lesions. Primary progressive multiple sclerosis, which affects approximately fifteen percent of newly diagnosed patients, is characterized by gradual disability accumulation from disease onset without a preceding relapsing phase, and predominantly affects the spinal cord, producing progressive myelopathy with gait disturbance, spasticity, bladder dysfunction, and ultimately wheelchair dependence in a significant proportion of patients within two decades of symptom onset.
Diagnosis and Monitoring
The diagnosis of multiple sclerosis relies on the demonstration of dissemination in space and time, meaning evidence of central nervous system lesions in at least two distinct anatomical locations and evidence that these lesions occurred at different points in time, through a combination of clinical history, neurological examination, magnetic resonance imaging of the brain and spinal cord, cerebrospinal fluid analysis, and evoked potential testing. The 2017 McDonald criteria provide the current diagnostic framework, incorporating magnetic resonance imaging findings that can substitute for a second clinical attack in demonstrating temporal dissemination and spatial dissemination in patients who have experienced a single clinical episode suggestive of multiple sclerosis.
Magnetic resonance imaging is the most sensitive diagnostic tool for multiple sclerosis, demonstrating the characteristic ovoid periventricular, juxtacortical, infratentorial, and spinal cord T2 hyperintense lesions that reflect areas of demyelination, edema, and glial scarring. Gadolinium-enhancing lesions indicate active blood-brain barrier breakdown at sites of acute inflammation and are a reliable marker of recent disease activity. Cerebrospinal fluid analysis demonstrating oligoclonal immunoglobulin bands absent from the serum, present in over ninety-five percent of multiple sclerosis patients, provides evidence of intrathecal immunoglobulin synthesis that supports the diagnosis in patients with clinically isolated syndromes not yet meeting magnetic resonance imaging criteria for spatial or temporal dissemination.
Disease-Modifying Therapies
The disease-modifying therapy landscape for relapsing multiple sclerosis has expanded dramatically, providing a spectrum of treatment options ranging from lower-efficacy, more broadly tolerated first-line agents to highly effective but more complex or risky high-efficacy therapies. Platform injectables including the interferon beta preparations and glatiramer acetate, the original disease-modifying therapies approved in the 1990s, reduce annual relapse rates by approximately thirty percent compared to placebo and provide a well-characterized long-term safety profile accumulated over decades of clinical use, but their modest efficacy makes them insufficient for patients with highly active disease requiring more aggressive control.
Oral disease-modifying therapies including dimethyl fumarate, teriflunomide, siponimod, ozanimod, and ponesimod provide the convenience of oral administration with efficacy profiles ranging from moderate to high depending on the agent, offering important alternatives for patients who prefer or require oral over injectable therapy. Natalizumab, a monoclonal antibody blocking alpha-4 integrin-mediated lymphocyte trafficking across the blood-brain barrier, provides approximately sixty-eight percent reduction in annual relapse rate and significant magnetic resonance imaging lesion suppression, representing one of the most effective therapies available for highly active relapsing multiple sclerosis. Ocrelizumab and ofatumumab, monoclonal antibodies depleting CD20-positive B lymphocytes, have established B lymphocyte depletion as one of the most effective pharmacological approaches to relapsing multiple sclerosis, achieving near-complete suppression of gadolinium-enhancing lesion activity and significant reductions in relapse rates and disability progression. Alemtuzumab and cladribine provide immune reconstitution approaches that produce highly durable disease control through their profound and selective depletion of the lymphocyte populations driving multiple sclerosis, with the potential for treatment-free remission periods following a short course of treatment.